Latest Danaher Corp News and Updates
Glenview Capital opens new position in Danaher
Glenview Capital Management added a new position in Danaher Corp. (DHR) in the third quarter. The position accounted for 1.99% of the fund’s total portfolio.
Sterne Agee CRT Rated Ecolab as a ‘Buy’
Ecolab (ECL) reported fiscal 4Q15 net sales of $3,412.0 million—a fall of 7.3% compared to net sales of $3,680.8 million in fiscal 4Q14.
What Wall Street Analysts Recommend for Dentsply Sirona
Dentsply Sirona (XRAY), one of the leading dental technology providers in the United States, recently outlined a turnaround plan to recover from the company’s disappointing performance in recent years.
ALGN Stock Surpasses the S&P 500 Index’s Year-to-Date Gain
On September 28, Align Technology (ALGN) posted an ~74% increase year-to-date. In the same period, the S&P 500 Index has returned ~9%.
Danaher Corporation’s Excess Returns Fail to Impress
Earlier in this series, we looked at Danaher’s return on invested capital on a standalone basis. However, we were only looking at half the story.
Credit Suisse Raised Ecolab Price Target to $109 per Share
Ecolab (ECL) reported fiscal 4Q15 net sales of $3,412.0 million, a fall of 7.3% compared to net sales of $3,680.8 million in fiscal 4Q14.
Glenview Capital increases stake in Fidelity National Financial
Glenview Capital Management added to its position in Fidelity National Financial (FNF) in the third quarter. Currently, the position accounts for 1.70% of the fund’s total portfolio.
Why Danaher Is Relatively Immune from Growth Concerns in China
Organically, Danaher (DGR) has grown at a CAGR of roughly 10% in China over the last five years. Approximately 50% of the company’s revenues in China are derived from its Diagnostics segment.
Verifone Systems Expands in 3Q15
Verifone Systems (PAY), with a market cap of $3.38 billion, is a leader in providing payment terminals, global payment as a service, and commerce enablement solutions.
Glenview Capital raises position in Endo International
Glenview Capital Management added to its position in Endo International Plc (ENDP) in the third quarter. Currently, the position accounts for 2.02% of the fund’s total portfolio.
Dover Fluids: A Brief Overview
Dover Corporation’s (DOV) Fluids businesses include the Pump Solutions Group (or PSG), which provides pumping solutions to several end markets.
Analysts Cut Their Targets for XRAY ahead of Its 1Q18 Results
Dentsply Sirona, one of the leading dental technology providers in the United States, will announce its 1Q18 earnings results on May 7.
Must-know: Why did firms report a sharp spike in wages in May?
Manufacturing growth appears to be steady in the Fifth District. Although new orders declined sharply month-on-month, firms remained upbeat for business prospects.
GE Stock Upgraded by UBS with a ‘Buy,’ $14 Price Target
Markus Mittermaier, a new analyst at UBS, gave GE stock a “buy” rating yesterday. Previously, UBS offered a “neutral” rating on the stock.
Will the New GE CFO Achieve Larry Culp’s Goals?
Today, GE announced that Carolina Dybeck Happe will take charge as chief financial officer or CFO at GE, replacing from Jamie Miller early next year.
Could Earnings and Culp Continue to Boost GE Stock?
The third quarter was tough for multinational conglomerate General Electric (GE). Between July 1 and September 30, GE stock lost 15% of its value.
Why do key purchasing managers’ index readings move markets?
In this series, we’ll focus on the manufacturing PMI issued by three major institutions, measuring manufacturing activity in the U.S.
GE Stock Gains, Citigroup Sees Meaningful Turnaround
On Wednesday, General Electric (GE) stock rose 5.6% after a top Wall Street analyst made some positive remarks about its turnaround efforts.
Align Technology Stock Recovers after Tanking Last Week
Align Technology stock (ALGN) took a massive hit after Q2 earnings. So what was behind the massive decline, and what’s helping the stock recover?
Could GE’s Q2 Results Surprise Investors Again?
General Electric (GE) is slated to report its Q2 results on Wednesday. Let’s look at what analysts expect from the company in the second quarter.
BioPharma Sale to Strengthen General Electric’s Balance Sheet
In late February, General Electric (GE) made a breakthrough toward reducing its debt obligation and strengthening its balance sheet.
GE Wraps Up Q1 with a 37% Gain in Its Stock Price
Shares of GE have been surging since the beginning of the year and have probably seen the highest gain ever in a first quarter.
GE Fell ~8% after J.P. Morgan Warned of More Downside Risk
GE stock extended its declines for the second consecutive day after a JPMorgan Chase analyst warned of more downside risk to the stock.
GE Soared after Larry Culp Stresses Debt Cut and Dividend Boost
General Electric (GE) was trading 1.4% higher in pre-market trading today after CEO Larry Culp reassured investors the company would return to a “position of strength.”
GE Shares Rose 2.5%, Analysts Turned Bullish on the Stock
On February 26, General Electric (GE) shares rose after several analysts provided positive comments about its recent deal.
Buffett Missing in Action as GE’s Turnaround Plan Gets Upvote
General Electric (GE) is up 9.1% today as of 11:50 AM ET. GE has announced that that it has entered a definitive agreement to sell its Biopharma business to Danaher (DHR).
Year-Long GE Transportation-Wabtec Merger Completed
General Electric (GE) closed the year-long pending merger of its Transportation business unit with Wabtec today.
GE Stock Rises on Announcement of BioPharma Unit Sale to Danaher
General Electric (GE) revealed today that it has entered a definitive agreement to sell its BioPharma business to Danaher.
Analysts Remain Bullish on Illumina Stock
In November, of the 19 analysts covering Illumina (ILMN), 14 have given it “buy” or higher ratings, and five have given it “hold” ratings.
Understanding Illumina’s Gross Margin Trend
Illumina’s cost of product revenue increased from $173.0 million in the third quarter of 2017 to $184.0 million in the third quarter of 2018.
Understanding Illumina’s Geographical Performance
For 2018 and 2019, Illumina is expected to generate revenues of $3.33 billion and $3.80 billion, respectively.
What Waters Corporation’s Valuation Trend Indicates
In September, of the 15 analysts covering Waters Corporation (WAT) stock, ten have given it “holds.”
Analyzing Perrigo’s Spin-Off of Its Rx Business
In this series, we’ll analyze major spin-offs in the healthcare sector by Perrigo (PRGO), Eli Lilly (LLY), Danaher (DHR), and Henry Schein.
Understanding Dentsply Sirona’s New Organizational Structure
In 4Q17, Dentsply Sirona (XRAY) started reporting its operations under two segments, after a shift to three segments in fiscal 3Q17.
Why Analysts Are Positive on W.R. Grace
In the past six months, the number of analysts covering W.R. Grace (GRA) has fallen from 14 to the present 11.
Why Is Wall Street Still Upbeat on Dentsply Sirona’s Growth Potential in 2018?
Dentsply Sirona is a leading dental technology, equipment, and consumables provider in the US. But it has been going through some tough times.
What Short Interest in Stanley Black & Decker Suggests
Data from February 28, 2018, shows that Stanley Black & Decker’s (SWK) short interest has fallen since the beginning of 2018.
Could Stanley Black & Decker Stock Bounce Back?
Stanley Black & Decker (SWK) stock has remained low since the beginning of 2018.
Developments in Dentsply Sirona’s Digital Dentistry Portfolio
On September 20, 2017, Dentsply Sirona (XRAY) announced an enhancement to its Galileos Implant software.
Dentsply Sirona’s Newly Launched Cerec Zirconia Meso Block
In August 2017, Dentsply Sirona (XRAY) launched its Cerec Zirconia Meso Block for creating customized screw-retained crowns.
What Analysts Are Recommending for Dentsply Sirona
According to the recommendations of 15 brokerage firms, 60.0% (or nine) of them have rated Dentsply Sirona (XRAY) a “buy,” and 33.0% (or five) have rated it a “hold.”
What Do Analysts Recommend for Dentsply Sirona?
Based on the recommendations of 16 brokerage companies, around 63% (or ten) of the analysts provided a “buy” recommendation for Dentsply Sirona.
Discussing Dentsply Sirona’s Updated 2017 Guidance
Dentsply Sirona made a downward revision to its fiscal 2017 guidance during the company’s 2Q17 earnings results announcement on August 9, 2017.
Dentsply Sirona’s Technologies Segment Sales Declined in 2Q17
In 2Q17, Dentsply Sirona’s (XRAY) Technologies business contributed ~44% to the company’s total revenues and registered sales of ~$439 million.
Align Technology Focuses on International Market Strategy
International market strategy In 2Q17, Align Technology (ALGN) reported 85,400 Invisalign case shipments in international markets, which is YoY (year-over-year) growth of ~37.4% and sequential growth of ~13.6%. This growth was mainly attributed to new customers in the EMEA (Europe, the Middle East, and Africa) and Asia-Pacific markets. If Align Technology continues to demonstrate solid […]
Inside Align Technology’s Market Expansion Strategy
In 1Q17, Align Technology (ALGN) also witnessed a robust rise of around 45.2% in volumes of Invisalign sold in Asia-Pacific markets on a YoY basis.
Understanding Align Technology’s Growing Position in International Markets
In 1Q17, Align Technology (ALGN) witnessed an 11.4% sequential rise in the volume of Invisalign cases used by doctors in international markets.
These Are Align Technologies Key Demand Drivers in North America
In 1Q17, Align Technology (ALGN) has started selling its new product Invisalign Go in North America, which involves a few DSOs (dental service organizations).
Behind Align Technology’s North American Expectations for 2017
In 1Q17, Align Technology’s (ALGN) Invisalign sales volumes in North American markets rose YoY by 20.3% and QoQ by 8.3%.
Why Align Technology’s Orthodontics Is a Solid Growth Opportunity in 2017
Align Technology (ALGN) is a medical device provider focused on malocclusion or teeth misalignment condition.
Inside Align Technology’s Robust Revenue Growth Projection for 2017
For fiscal 2017, Align Technology (ALGN) expects its 2017 revenues to grow operationally in the range of 15%–25% YoY.
Align Technology versus Peers in June 2017: Analyst Recommendations
For 1Q17, Align Technology (ALGN) reported revenues close to $310.3 million, which represents YoY (year-over-year) growth of around 30.0%.
What Bio-Rad Laboratories Expects from Life Science
In 1Q17, Bio-Rad Laboratories’ (BIO) Life Science segment reported revenues of ~$174.3 million, which represents a YoY rise of ~5.1%.
Inside Bio-Rad Laboratories’ Robust Revenue Growth Projection for 2017
On March 13, 2017, Bio-Rad Laboratories (BIO) provided a long-term, currency-neutral revenue growth target of around 3%–5%.
Bio-Rad Laboratories on the Street: Analysts’ Recommendations in May
In 1Q17, Bio-Rad Laboratories (BIO) reported revenues of ~$500.1 million, which represented a YoY (year-over-year) rise of around 6.1%.
Dentsply Sirona’s New Growth Strategy to Accelerate Digital Dentistry Penetration
Dentsply Sirona is the largest dental equipment and solutions manufacturer in the United States. Digital dentistry is a megatrend in the market.
How Did Danaher’s Operating Segments Fare in 4Q16?
Currently, Danaher (DHR) reports its revenue under four operating segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Why Danaher Stock Rose after Its 4Q16 Results
Danaher Corporation (DHR) announced its 4Q16 and 2016 earnings results before the market opened on January 31, 2017. Let’s take a look.
What Factors Could Drive Danaher Stock in 2017?
Danaher Corporation (DHR) will announce its 4Q16 earning results before the market opens on January 31, 2017. What should we expect?
Ecolab Declares a Dividend of $0.37 per Share
Price movement Ecolab (ECL) has a market cap of $35.4 billion. It rose 0.67% to close at $119.61 per share on December 8, 2016. The stock’s weekly, monthly, and year-to-date (or YTD) price movements were 0.95%, 5.3%, and 5.5%, respectively, on the same day. ECL is trading 3.0% above its 20-day moving average, 2.7% above […]
With Phenomenex, Danaher Has an Attractive Consumables Asset
On October 12, Danaher announced its an agreement to acquire Phenomenex, a privately held manufacturer of separation and purification consumables.
Why the T. Rowe Price Blue Chip Growth Fund Has Had a Rough 2016
TRBCX has had quite a poor run in 2016 so far. The fund places in the bottom three in the YTD period among the 12 funds in this review.
What Made Cepheid Attractive to Danaher?
On September 6, 2016, Danaher (DHR) announced that it has entered into a definitive agreement to acquire Cepheid (CPHD) for $4 billion.
How Danaher Diagnostics Fares against Its Competition
Danaher’s Diagnostics unit had operating margins of 15.4% in 2015 and 17.2% in 1H16.
The Key Product Lines That Make Up Danaher’s Diagnostics Business
Danaher’s (DHR) Diagnostics unit, established through the acquisition of Radiometer in 2004, earned $4.9 billion in sales in 2015.
Pall Acquisition Gave Birth to Danaher’s Filtration Business
Danaher’s filtration business came into existence through the acquisition of Pall in 2015.
Understanding the Skeleton of Danaher’s Life Sciences Business
Customers in the Danaher life sciences business generally look at how the technology offered by a company can fit into their workflows.
How Are Danaher’s Returns Compared to Its Industry Peers’?
Danaher’s ROIC fell steadily from 15.5% in 2006 to 8.5% in 2015, indicating that it has probably had fewer high return reinvestment opportunities since then.
Is Danaher Losing Its Competitive Advantage?
We analyzed Danaher’s (DHR) ROIC in the 20-year period between 1995 and 2015 and classified the period of study into 16 buckets of five years each.
Danaher’s Journey from Corporate Raider to Corporate Statesman
Danaher (DHR) was the brainchild of brothers Steven and Mitchell Rales. It was incorporated as a holding company in 1984.
Parker-Hannifin’s 2017 Guidance Suggests Slowdown in Industrials
Parker-Hannifin has guided its fiscal 2017 adjusted EPS at $6.40–$7.10. The midpoint of this range is roughly 4.5% higher than $6.46 in fiscal 2016.
Noteworthy Portfolio Changes in the MFS Growth Fund
The MFS Growth Fund Class A’s assets were invested across 87 holdings as of June 2016, and it was managing assets worth $12 billion as of the end of June.
Ecolab Invests in Aquatech International to Improve Processes
Ecolab fell by 0.26% to close at $120.95 per share on July 15, 2016. Its weekly, monthly, and YTD price movements were 1.5%, 2.3%, and 6.4%, respectively.
How Wall Street Views Dover Corporation’s 2Q16 Earnings
The diversified industrials company Dover Corporation (DOV) is expected to declare its 2Q16 earnings on July 19, 2016. In 1Q16, Dover’s management downgraded its sales guidance, citing weaker fundamentals in the oil and gas markets
Ecolab Acquires Anios and Sees Its Target Price Cut
Ecolab (ECL) has a market cap of $34.3 billion. Its stock rose by 1.3% to close at $116.79 per share on June 29, 2016.
How 3M Company Differs from Other Industrial Conglomerates
While 3M’s peer group includes industrial conglomerates such as Honeywell and General Electric, these companies hardly share any similarities with 3M.
Emera US Finance Issued the Most High Grade Bonds Last Week
Yankee bond issuers dominated the primary high grade bond market in the week ended June 10, making up 30.3%, or $10.2 billion, of all issues.
Understanding Dover Corporation’s Corporate Profile and History
Dover Corporation (DOV) is a machinery manufacturer that operates in four diverse segments: Energy, Engineered Systems, Fluids, and Refrigeration & Food Equipment.
Why Goldman Sachs Downgraded Ecolab to ‘Sell’
Ecolab has a market cap of $30.5 billion. It fell and closed at $103.04 per share as of March 14. In fiscal 2015, it reported net sales of $13,545.1 million.
Why Barclays Reduced Ecolab’s Price Target
Ecolab (ECL) has a market cap of $30.2 billion. ECL rose by 2.0% to close at $102.13 per share as of February 24, 2016.
How Does Ecolab Compare to Its Peers?
The PowerShares Water Resource Portfolio (PHO) invests 7.5% of its holdings in Ecolab.
Becton, Dickinson and Company’s Acquisitions and Collaborations
Becton, Dickinson and Company’s (BDX), or BD’s, growth strategy includes acquisitions and collaborations.
Cantel Medical’s Revenue and Income Rise in Fiscal 1Q16
Cantel Medical (CMN) has a market cap of $2.8 billion. Its YTD (year-to-date) price has been rising quarter-over-quarter in calendar 2015.
Analyzing Sirona Dental Systems’ Rise in Revenue in Fiscal 4Q15
After the release of Sirona Dental Systems’ (SIRO) 4Q15 earnings report, SIRO rose by 0.23% to close at $109.22 per share on November 20, 2015.
Why the Federal Manufacturing Index Fell in October
With new orders and shipments indexes turning negative, the Philadelphia Fed Manufacturing Index came in at -4.5 points in October 2015.
How Does Abbott Compare With Its Peers in the Industry?
The PE multiple is one of the simplest multiples used for valuations. The forward PE ratio for Abbott is ~22x for 2015. It’s ~23.7x for the industry.
Understanding Leverage for Abbott Laboratories
Abbott Laboratories (ABT) uses both equity and debt for its working capital requirements as well as investments in the business.
What Is UTC Building & Industrial Systems?
UTC offers some products and services through UTC Building & Industrial Systems, a combination of two segments, Otis and UTC Climate, Controls & Security.
The Boeing Company’s Narrow-Body Aircraft
The Boeing 737 is the best-selling commercial airliner in history. Reliable and economical, the 737 dominates the short- and medium-haul markets.
What to Expect from Boeing’s New Pension Plan
Boeing offered some former nonunion employees the option of taking a lump-sum payment or an annuity to replace their traditional pension benefits.
Glenview Capital ups position in Pentair
Glenview Capital Management added to its position in Pentair Plc (PNR) in the third quarter. Currently, the position accounts for 2.41% of the fund’s total portfolio.